A Phase 3, Open-Label Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER (Open-Label Extension)
Phase of Trial: Phase III
Latest Information Update: 29 Jan 2018
At a glance
- Drugs Adalimumab (Primary)
- Indications Hidradenitis suppurativa
- Focus Therapeutic Use
- Acronyms PIONEER-OLE
- Sponsors AbbVie
- 26 Sep 2016 Status changed from active, no longer recruiting to completed.
- 21 Jul 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Jul 2016.
- 25 Jan 2016 Planned End Date changed from 1 Mar 2016 to 1 Sep 2016, according to ClinicalTrials.gov record.